Over the last two decades, more than one hundred mAbs have been approved or are in regulatory review in the US and EU. This growth has led to an increasing need for developing rapid technologies to support the characterization of mAbs to secure drug product safety, quality, and efficacy. In this presentation we present several mass spectrometry-based technologies used in a stage appropriate manner to dramatically shorten timelines and improve throughput in biologics research. Examples include; automated and rapid sample preparation, multiplexed workflows, high-resolution SLIM-IMS-MS, RapidFire-MS, and our labs ongoing efforts for an end-to-end automated process from sample preparation to reporting.

For Research Use Only. Not for use in diagnostic procedures.